我武生物(300357) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 164,654,385.39, representing a 49.31% increase compared to CNY 110,275,663.26 in the same period last year[8]. - Net profit attributable to shareholders was CNY 70,454,208.66, a 70.31% increase from CNY 41,368,706.64 year-over-year[8]. - The company achieved operating revenue of CNY 164,654,385.39, an increase of 49.31% compared to the same period last year[26]. - The net profit attributable to shareholders reached CNY 70,454,208.66, reflecting a growth of 70.31% year-on-year[26]. - The company reported a total profit of ¥80,882,386.26 for the current period, up from ¥47,975,664.52 in the previous period, marking an increase of around 68.5%[81]. - The company reported a total comprehensive income of ¥67,728,189.15 for the current period, compared to ¥40,235,491.85 in the previous period, reflecting a growth of approximately 68.3%[84]. Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 99,954,766.48, up 47.60% from CNY 67,719,778.94 in the previous year[8]. - Cash inflow from operating activities totaled ¥208,110,123.73, up from ¥160,933,608.23, reflecting a growth of approximately 29.3%[96]. - Cash and cash equivalents increased by CNY 100,408,803.99, a significant rise of 182.66% due to improved cash flow from operations and investments[25]. - Cash and cash equivalents at the end of the period were ¥376,413,028.97, up from ¥204,794,812.25, reflecting an increase of approximately 83.5%[98]. - The company experienced a net increase in cash and cash equivalents of ¥155,378,384.69, compared to ¥54,969,580.70 in the previous period, showing strong liquidity growth[98]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,690,191,869.39, reflecting a 5.32% increase from CNY 1,604,755,527.30 at the end of the previous year[8]. - Current liabilities rose to CNY 64,949,417.92, compared to CNY 55,419,690.55, indicating an increase of approximately 17.36%[63]. - Total liabilities reached CNY 94,315,851.61, up from CNY 76,607,698.67, marking a growth of around 23.14%[63]. - Owner's equity increased to CNY 1,595,876,017.78 from CNY 1,528,147,828.63, showing a growth of about 4.42%[66]. - Non-current assets totaled CNY 456,869,820.84, an increase from CNY 433,817,332.64, reflecting a growth of about 5.73%[66]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,588[12]. - The largest shareholder, Zhejiang Wowo Management Consulting Co., Ltd., held 38.86% of the shares[13]. Research and Development - Research and development expenses rose by CNY 9,229,096.19, an increase of 84.50%, driven by enhanced investment in stem cell and natural medicine research[24]. - The newly developed product, "Artemisia Annua Pollen Allergen Sublingual Drops," received regulatory approval on January 30, 2021, but large-scale sales will take time, highlighting ongoing reliance on existing products[34]. - The company plans to enhance the promotion of "Artemisia Annua Pollen Allergen Sublingual Drops" to expedite its market entry and reduce reliance on existing products[34]. Government Subsidies and Other Income - The company received government subsidies amounting to CNY 10,083,635.66 during the reporting period[8]. - The company received government subsidies related to daily operations, resulting in other income increasing by CNY 10,200,362.77, a staggering growth of 568,632.81%[24]. Risks and Challenges - The company faces risks related to industry policy changes and potential price reductions in drug tenders, which may impact future performance[29]. - The company faces risks in new drug development due to stringent regulatory requirements, which can delay market entry and affect competitiveness if clinical trials do not meet expectations[35]. - The company has faced challenges in ensuring new drugs gain market acceptance, which could impact sales volume if they lack competitiveness[35]. Investment and Projects - The company has received approval from the China Securities Regulatory Commission for a specific stock issuance to fund projects, including a natural medicine utilization base and an animal testing center[36]. - The company terminated the "Marketing Network Expansion and Information Technology Construction Project" and will permanently supplement the remaining raised funds of CNY 2,888.52 million into working capital[48]. - The "Annual Production of 3 Million Dust Mite Drops Technology Renovation Project" has an actual investment of CNY 11,427.52 million, achieving 97.92% of the planned investment[45]. - The "Allergen Research and Development Center Technology Renovation Project" has an actual investment of CNY 4,429.32 million, achieving 94.95% of the planned investment[45].